(Q38163227)

30 August 2017

title

Precision medicine for metastatic renal cell carcinoma (English)

1 reference

30 August 2017

2

Toni K Choueiri

1 reference

30 August 2017

Guru Sonpavde

1

1 reference

30 August 2017

publication date

13 November 2013

1 reference

30 August 2017

1 reference

30 August 2017

volume

32

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

5-15

1 reference

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Modes of resistance to anti-angiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

The tuberous sclerosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Birt-Hogg-Dubé syndrome: diagnosis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Sequential sorafenib and sunitinib for renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Magnetic resonance imaging as a biomarker in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Metabolism of kidney cancer: from the lab to clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Tissue biomarkers in renal cell carcinoma: issues and solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Reporting recommendations for tumor marker prognostic studies (REMARK).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.07.010

10.1016/J.UROLONC.2013.07.010

7 January 2021

Identifiers

DOI

1 reference

release_kgw6njdxgrgexk3eqwvevvtwf4

30 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kgw6njdxgrgexk3eqwvevvtwf4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference